More importantly, genetic or pharmaceutical blockade of CXCR2 reduces tumorigenesis and angiogenesis in mice with oesophageal cancer, lung cancer, breast cancer and pancreatic cancer (Keane et al., 2004; Wislez et al., 2006; Matsuo et al., 2009; Xu et al., 2018). Here, CXCR2 is linked to carcinoma of esophagus.